Market Overview

UPDATE: Intrexon to Acquire Medistem for $26M

Related XON
ZIOPHARM, Intrexon Offer Clinical, Preclinical Data from Immuno-Oncology Programs: Showed Anti-Cancer Activity, Planning Phase 1b/@ Trial AD-RTS-HIL-12 with Veledimex
What's Driving Up Intrexon?

Intrexon Corporation (NYSE: XON) today announced that it has entered into a definitive agreement to acquire, for approximately $26 million, San Diego-based Medistem, Inc. (OTC: MEDS) a pioneer in the development of Endometrial Regenerative Cells ("ERC" or "ERCs"), universal donor adult stem cells that stimulate new blood vessel formation and are capable of generating different tissues including heart, brain, pancreas, liver, bone, cartilage and lung. Intrexon intends to employ its integrated synthetic biology platforms to engineer a diverse array of cell-based therapeutic candidates using Medistem's multipotent ERCs.

See full press release

Posted-In: News Guidance Dividends Contracts Management Global

 

Related Articles (MEDS + XON)

Around the Web, We're Loving...

Get Benzinga's Newsletters